Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena|||0000-0001-8128-9528
  • Grinyó-Escuer, Ariadna|||0000-0003-0185-2734
  • Duro Sánchez, Santiago|||0000-0002-3829-7562
  • Rius-Ruiz, Irene
  • Bort-Brusca, Marta
  • Escorihuela, Marta|||0000-0001-9074-2339
  • Maqueda-Marcos, Susana
  • Pérez-Ramos, Sandra|||0000-0002-3612-4027
  • Gago, Judit
  • Nogales, Vanesa
  • Espinosa-Bravo, Martín|||0000-0002-4293-3875
  • Peg, Vicente|||0000-0002-5203-6166
  • Escrivá-de-Romaní, Santiago|||0000-0001-7816-7589
  • Foradada Felip, Laia|||0000-0002-0589-4360
  • Soucek, Laura|||0000-0002-4750-7971
  • Braña, Irene|||0000-0002-1068-9601
  • Galvao, Vladimir
  • Martín-Lluesma, Silvia|||0000-0001-7491-1876
  • Moessner, Ekkehard
  • Klein, Christian|||0000-0001-7594-7280
  • Garralda, Elena|||0000-0002-4412-7842
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors. Chimeric antigen receptor T (CAR-T) cell therapy is efficient in certain haematologic malignancies, but clinical success in solid tumours has been hampered by scarcity of tumour-specific antigens. Here authors show that combination therapy using CAR T cells targeting p95HER2 and bispecific antibodies against HER2 and CD3 consistently leads to complete regression in HER2-positive, patient-derived xenografts tumours in mouse models.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena
  • Duro-Sánchez, Santiago
  • Bort-Brusca, Marta
  • Gago, Judit
  • Nogales, Vanesa
  • Arribas, Joaquín
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors., M.R.A. was supported by Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya (AGAUR-FI-DGR to M.R.A.). A.G.-E. received the support of a fellowship from the Predoctoral fellowship INPhINIT "la Caixa" Programme by "la Caixa"Foundation (LCF/BQ/DI21/118600412021 to A.G.-E.). S.D.-S. acknowledges the Spanish Ministerio de Universidades for a Formación de Profesorado Universitario grant (FPU20/05388 to S.D.-S). J.A. acknowledges the financial support for this study from the Fundación Científica de la Asociación Española contra el Cáncer (FCAECC) (GCAEC19017ARRI and INNOV235333ARRI to J.A.) and the AECC EXCELLENCE ADVANCED THERAPIES ACCELERATOR PROGRAM (EPAEC222644VHIO to VHIO). In addition, this work has received support from the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking Immune-Image grant (831514 to J.A.). This study was also partially supported by a grant from the Breast Cancer Research Foundation (BCRF-21-008 to J.A.), by the Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, through the projects CB16/12/00449, PMP22/00054 and PI19/01181 (to J.A.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II), supported by the BBVA Foundation (grant 53/2021 to J.A.). VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033 to VHIO), the Cellex Foundation for providing research facilities and equipment, and the CERCA Programme from the Generalitat de Catalunya for their support of this research.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study

  • Borrego Yaniz, Gonzalo
  • Ortiz-Fernández, Lourdes
  • Madrid-Paredes, Adela
  • Kerick, Martin
  • Hernández-Rodríguez, José
  • Mackie, Sarah
  • Vaglio, Augusto
  • Castañeda, Santos
  • Solans, Roser
  • Khalidi, Nader
  • Langford, Carol
  • Ytterberg, Steven R.
  • Beretta, Lorenzo
  • Govoni, Marcelo
  • Emmi, Giacomo
  • Cimmino, Marco A.
  • Witte, Torsten
  • Neumann, Thomas
  • Holle, Julia
  • Schönau, Verena
  • Pugnet, Gregory
  • Papo, Thomas
  • Haroche, Julien
  • Mahr, Alfred
  • Mouthon, Luc
  • Molberg, Oyvind
  • Diamantopoulos, Andreas P.
  • Voskuyl, Alexandre E.
  • Daikeler, Thomas
  • Berger, Christoph
  • Molloy, Eamonn
  • Blockmans, Daniel
  • Ortego-Centeno, Norberto
  • Brouwer, Elisabeth
  • Lamprecht, Peter
  • Klapa, Sebastian
  • Salvarani, Carlo
  • Merkel, Peter A.
  • Cid, María C.
  • González-Gay, Miguel A.
  • Morgan, Ann W.
  • Martín, Javier
  • Márquez, Ana
  • Spanish GCA Study Group
  • UK GCA Consortium
  • Vasculitis Clinical Research Consortium
et al., [Background] Giant cell arteritis is an age-related vasculitis that mainly affects the aorta and its branches in individuals aged 50 years and older. Current options for diagnosis and treatment are scarce, highlighting the need to better understand its underlying pathogenesis. Genome-wide association studies (GWAS) have emerged as a powerful tool for unravelling the pathogenic mechanisms involved in complex diseases. We aimed to characterise the genetic basis of giant cell arteritis by performing the largest GWAS of this vasculitis to date and to assess the functional consequences and clinical implications of identified risk loci., [Methods] We collected and meta-analysed genomic data from patients with giant cell arteritis and healthy controls of European ancestry from ten cohorts across Europe and North America. Eligible patients required confirmation of giant cell arteritis diagnosis by positive temporal artery biopsy, positive temporal artery doppler ultrasonography, or imaging techniques confirming large-vessel vasculitis. We assessed the functional consequences of loci associated with giant cell arteritis using cell enrichment analysis, fine-mapping, and causal gene prioritisation. We also performed a drug repurposing analysis and developed a polygenic risk score to explore the clinical implications of our findings., [Findings] We included a total of 3498 patients with giant cell arteritis and 15 550 controls. We identified three novel loci associated with risk of giant cell arteritis. Two loci, MFGE8 (rs8029053; p=4·96 × 10–8; OR 1·19 [95% CI 1·12–1·26]) and VTN (rs704; p=2·75 × 10–9; OR 0·84 [0·79–0·89]), were related to angiogenesis pathways and the third locus, CCDC25 (rs11782624; p=1·28 × 10–8; OR 1·18 [1·12–1·25]), was related to neutrophil extracellular traps (NETs). We also found an association between this vasculitis and HLA region and PLG. Variants associated with giant cell arteritis seemed to fulfil a specific regulatory role in crucial immune cell types. Furthermore, we identified several drugs that could represent promising candidates for treatment of this disease. The polygenic risk score model was able to identify individuals at increased risk of developing giant cell arteritis (90th percentile OR 2·87 [95% CI 2·15–3·82]; p=1·73 × 10–13)., [Interpretation] We have found several additional loci associated with giant cell arteritis, highlighting the crucial role of angiogenesis in disease susceptibility. Our study represents a step forward in the translation of genomic findings to clinical practice in giant cell arteritis, proposing new treatments and a method to measure genetic predisposition to this vasculitis., Institute of Health Carlos III, Spanish Ministry of Science and Innovation, UK Medical Research Council, and National Institute for Health and Care Research, MCC reports support from the Spanish Ministry of Science and Innovation (PID2020-114909RB-I00), EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking Immune-Image grant no 831514. LO-F was supported by a Juan de la Cierva Incorporación fellowship (IJC2019-040746-I), funded by MCIN/AEI/10.13039/501100011033., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

  • Román Alonso, Macarena
  • Duro-Sánchez, Santiago
  • Bort-Brusca, Marta
  • Gago, Judit
  • Nogales, Vanesa
  • Arribas, Joaquín
The redirection of T lymphocytes against tumor-associated or tumor-specific antigens, using bispecific antibodies or chimeric antigen receptors (CAR), has shown therapeutic success against certain hematological malignancies. However, this strategy has not been effective against solid tumors. Here, we describe the development of CAR T cells targeting p95HER2, a tumor-specific antigen found in HER2-amplified solid tumors. These CAR T cells display robust activity against p95HER2-expressing cell lines but demonstrate limited efficacy against patient-derived xenografts. As p95HER2 is invariably detectable on tumor cells that overexpress HER2, but not those that express HER2 at normal levels, we arm p95HER2-specific CAR T cells with affinity-tuned bispecific antibodies against HER2 and CD3 in order to redirect them only to HER2-amplified cells. The combination of p95HER2.CAR T cells and HER2 x CD3 bispecific antibodies lead to a complete regression in three HER2-positive, patient-derived mouse xenografts tumor models. This combination represents a promising strategy to redirect T cells against a subset of HER2-positive tumors., M.R.A. was supported by Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya (AGAUR-FI-DGR to M.R.A.). A.G.-E. received the support of a fellowship from the Predoctoral fellowship INPhINIT "la Caixa" Programme by "la Caixa"Foundation (LCF/BQ/DI21/118600412021 to A.G.-E.). S.D.-S. acknowledges the Spanish Ministerio de Universidades for a Formación de Profesorado Universitario grant (FPU20/05388 to S.D.-S). J.A. acknowledges the financial support for this study from the Fundación Científica de la Asociación Española contra el Cáncer (FCAECC) (GCAEC19017ARRI and INNOV235333ARRI to J.A.) and the AECC EXCELLENCE ADVANCED THERAPIES ACCELERATOR PROGRAM (EPAEC222644VHIO to VHIO). In addition, this work has received support from the EU/EFPIA/Innovative Medicines Initiative 2 Joint Undertaking Immune-Image grant (831514 to J.A.). This study was also partially supported by a grant from the Breast Cancer Research Foundation (BCRF-21-008 to J.A.), by the Instituto de Salud Carlos III (ISCIII), co-funded by the European Union, through the projects CB16/12/00449, PMP22/00054 and PI19/01181 (to J.A.), and by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II), supported by the BBVA Foundation (grant 53/2021 to J.A.). VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033 to VHIO), the Cellex Foundation for providing research facilities and equipment, and the CERCA Programme from the Generalitat de Catalunya for their support of this research.